Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.
about
Generation of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysisUp-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acidMHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cellsT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyCancer/testis antigens: an expanding family of targets for cancer immunotherapyRegulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cellsDistinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanomaHigh-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes.Epigenetic Strategies to Boost Cancer Immunotherapies.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionEpigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesHistone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.Epigenetics and DNA methylation come of age in toxicology.Potential target antigens for a universal vaccine in epithelial ovarian cancer.Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cellsHistone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cellsEpigenetic regulation of differential HLA-A allelic expression levels.CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and KillingTreatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesRole of gene methylation in antitumor immune response: implication for tumor progression.Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cellsHLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceCombination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Histone deacetylases and the immunological network: implications in cancer and inflammation.Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.Unravelling the complexity of cancer-immune system interplay.Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.Immunotherapy of MHC class I-deficient tumors.
P2860
Q24288913-B24213E5-B3A0-434E-9575-7636210B794AQ24288944-04E0222B-93D8-4D40-8D07-F27D8D7DECF3Q26866479-58330CFF-3185-481A-8A62-7397E171CEADQ28074619-636BC98D-57C5-4F31-A4BE-BD6B2664FBC3Q28076473-1C030986-8AAB-4B72-AAF5-F7D3543D0FF0Q28215652-1E7584D3-537F-47EC-8B97-63F4B385DF2FQ28291291-F397926E-E391-4671-9829-37FE1DF8A472Q30830061-589BFA51-F527-4431-9D93-C9E698CF4128Q33551404-1387813C-E53A-4D4D-8ABE-757AEA92130EQ33762715-B145708B-6096-4E1B-9934-E86A3E0BD82AQ33808063-B672F2EE-9D7B-4B7F-AEF1-F9E2DD3568BDQ33838340-FEE0D182-812E-46CF-8594-5C1492CC0A93Q33931434-68087518-D2EA-46AF-97A2-F023A55E111BQ33980682-FAF1E5E4-A06F-4CDE-AD5D-6CCE420634DFQ34060387-4FF69EE6-A737-4A49-A447-ACDF40197B5DQ34124480-17369E26-6CC2-470A-8144-814D94BFFC1FQ34159451-6CD6018E-B538-4A36-806B-9961DFE60E21Q34775318-2D67C927-3865-4B24-ADC0-546D407DD402Q35005940-298E8A8D-AA0E-4D42-92B1-A8F3F8B76DF4Q35067995-D88D0495-5F05-4D20-BFB9-5CE25FE41526Q35136002-51042DA0-F657-45F1-85FF-C76FCBB7B858Q35821131-DDAC844A-0374-49D3-9630-C731847951AFQ36067682-F087B060-6ABD-446D-9E6A-EF13A30692E1Q36118290-CEF2E6C7-4355-4F60-A803-D343E199297AQ36136992-6B2C90EA-A73F-4901-AF57-B17C66A8A2BCQ36283696-E6767DAC-BAAA-43C6-BF8A-7559F307CF08Q36407481-A26718F6-F3DC-4C77-9346-F29F0807768DQ36459332-714E1B1B-B2F6-4029-8C1B-20A98F823529Q36786757-AAED87A6-B12F-415B-9EAB-8A8FE9B0D9D0Q36801625-DD366BDB-8E1C-4BAF-A1B0-75DD2FD5D03EQ36831746-5575B408-734D-4B65-8CF0-BA2AC87C05B4Q37132658-1F10BEEC-B532-47F7-A01D-F1065AB933FEQ37285301-C2FB5886-DEDE-41A0-9C91-0A2AA8421A90Q37287152-2292B99F-3E1D-4ED3-B256-DA0193A6B666Q37299843-75560BFF-DACA-4C66-8633-7BBAEE961F96Q37621256-29FD352C-F0AE-4AA1-8579-CF361D5A6D5EQ37735806-01CE08A0-4F95-471B-B265-3F87C89EFB87Q37765590-5146386A-6514-44ED-BCF8-F6E3710C11FDQ37773238-923DB91F-F81E-4325-ADD1-08A985DEFF3AQ37808218-A36C6B97-4A87-4082-AC09-CD4606A0451E
P2860
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@en
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@nl
type
label
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@en
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@nl
prefLabel
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@en
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@nl
P2093
P2860
P356
P1476
Rexpression of HLA class I ant ...... za-2'-deoxycytidine treatment.
@en
P2093
C Traversari
F Ruiz-Cabello
I Lionello
S Tanzarella
P2860
P304
P356
10.1002/IJC.1452
P577
2001-10-01T00:00:00Z